άÐÞ¼¼ÊõÔ±/¹¤³Ìʦ н×ÊÃæÒé ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐÆ¸ > άÐÞ¼¼ÊõÔ±/¹¤³Ìʦ

άÐÞ¼¼ÊõÔ±/¹¤³Ìʦ

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2021-04-15±»ä¯ÀÀ£º1255´Î

н×ÊÃæÒé

²»ÏÞ / ÖÐר / ÐÔ±ð²»ÏÞ / 5 / ²»ÏÞµ½¸Ú

½­ËÕ-Ì©ÖÝ £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© Éϰà·Ïß²éѯ

ÕÐÆ¸5

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíÈ¨Òæ£¬¾¯ÌèÐé¼ÙÕÐÆ¸,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

¸ÚλְÔð£º1ÊìϤÁª¶¯Ïß¼°¶³¸É»úµÄÈÕ³£Î¬ÐÞ¼°Î¬»¤±£Ñø£»

2²ÎÓëÉ豸ÉèÊ©µÄÖÜÆÚÐÔάÐ޼ƻ®µÄÖÆ¶¨ºÍʵʩ£»

3²ÎÓëÉ豸Éèʩά»¤Î¬ÐÞSOPÈ·ÈÏÎļþµÄ±àд£»

4É豸·¢Éú¹ÊÕÏʱµÄ½ô¼±Î¬ÐÞ£¬È·±£²»Ó°ÏìÕý³£µÄÉú²úÔËÐÐ;
5É豸µÄ±¸Æ·±¸¼þ¹ÜÀí£¬±£Ö¤×îµÍ¿â´æ£¬È·±£²»Ó°ÏìÕý³£µÄÉú²úÔËÐУ»

6¶ÔÉ豸ά»¤±£Ñø¼Ç¼½øÐÐÉóºËͳ¼ÆºÍ·ÖÎö£¬Ìá¸ßÉ豸µÄά»¤Ð§ÂʺÍÉ豸µÄÔËÐпɿ¿ÐÔ£¬½µµÍÉ豸µÄÍ£»

úÂÊ£»

7¸ø²Ù×÷ÈËÔ±ºÍάÐÞÈËÔ±ÌṩÏà¹Ø¼¼ÊõÅàѵ£»

8Íê³ÉÁìµ¼½»°ìµÄÆäËû¹¤×÷ÈÎÎñ¡£
ÈÎÖ°ÒªÇó£º1´óרÒÔÉÏѧÀú£¬µçÆø»ò»úеµÈÏà¹Ø×¨Òµ£»

21ÄêÒÔÉÏÒ©³§Éú²ú»ò¶¯Á¦É豸άÐÞ¾­ÑéÓÅÏÈ£»

3Óнø¿ÚÉ豸άÐÞ¾­ÑéÓÅÏÈ£»

4Óе繤֤£¨Æ«»úеάÐÞÈËÔ±¿É²»ÐèÒª£©£»

5»áʹÓÃAUTOCADµÈ¹¤³ÌÖÆÍ¼Èí¼þ£»

6Á˽âGMP·¨¹æÖªÊ¶ÕßÓÅÏÈ£»

7¾ßÓнÏÇ¿µÄ×é֯Эµ÷ÄÜÁ¦ÓëÍŶӺÏ×÷¾«Éñ¡£

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàÆ½·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖÆ±¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖØµãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøÐ¼²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • ½­ËÕ-Ì©ÖÝ
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
0¸öÕÐÆ¸Ö°Î»
ְλÃû³Æ£ºÎ¬ÐÞ¼¼ÊõÔ±/¹¤³Ìʦ
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆÖ°Î»
  • µçÆø¼¼ÊõÔ±
    6ǧ-1Íò2/Ô ̩ÖÝ-Ì©ÐË
    ½­ËÕº¼¸»»·±£¿Æ¼¼ÓÐÏÞ¹«Ë¾
  • άÐÞ¾­Àí
    ÃæÒé Ì©ÖÝ-Ì©ÐË
    ÍþÁ¢ÑÅ»·±£¿Æ¼¼£¨Ì©ÐË£©ÓÐÏÞ¹«Ë¾